In the era of rising antibiotic resistance, Meropenem + Sulbactam 1.5 gm injection stands out as a critical-care antibiotic combination used for life-threatening infections. This broad-spectrum injectable is widely prescribed in hospitals and ICUs across India for multi-drug resistant (MDR) and ESBL-producing bacterial infections.
To meet the growing demand for this lifesaving antibiotic, several top Meropenem Sulbactam 1.5 gm manufacturers in India have emerged as trusted suppliers. In this comprehensive blog, we cover everything about Angopenem-SB ( Meropenem + Sulbactam 1.5 gm) you need to know—from its mechanism and uses to side effects, precautions, and why certain manufacturers are preferred in the PCD pharma franchise market.
Meropenem + Sulbactam 1.5 gm is a fixed-dose combination injectable antibiotic.
The combination is supplied as a sterile powder in a vial, reconstituted with sterile water or saline before intravenous administration. It is reserved for serious infections where narrower antibiotics fail.
Meropenem alone is highly effective, but many Gram-negative bacteria (like Klebsiella, Pseudomonas, Acinetobacter, and ESBL-producing E. coli) produce beta-lactamase enzymes that destroy carbapenems. Adding sulbactam inhibits these enzymes, restoring meropenem’s potency and providing broader coverage against resistant strains — especially in hospital-acquired infections. This makes the combination superior to meropenem alone in regions with high resistance rates, such as India.
The synergy results in potent activity against:
It is used only when culture-sensitivity reports confirm susceptibility or in empiric therapy for suspected resistant infections. Typical dose: 1.5 gm IV every 8 hours (adjusted for renal function).
Common indications:
| Condition | Typical Pathogens Covered |
| Nosocomial Pneumonia | Pseudomonas, Acinetobacter, Klebsiella |
| Intra-abdominal Infections | Polymicrobial (anaerobes + Gram-negative) |
| Sepsis / Bacteremia | MDR Gram-negative bacteria |
| Complicated UTI / Pyelonephritis | ESBL E. coli, Klebsiella |
| Skin & Soft Tissue Infections | Resistant Staphylococcus & Gram-negative |
| Meningitis | Streptococcus pneumoniae, Neisseria |
Most side effects are mild and transient:
Choosing the right Meropenem + Sulbactam manufacturer is crucial because injectable antibiotics fall under critical-care, high-risk pharmaceutical products. A trusted brand must comply with:
Ensures:
Shows adherence to:
Each batch undergoes:
This guarantees that every vial of Meropenem + Sulbactam is safe, potent, and contamination-free.
Aingo Pharma’s Angopenem-SB complies with all three standards, making it one of the most trusted brands in India.
Step 1: Bacteria release beta-lactamase enzymes → degrade standard antibiotics
Step 2: Sulbactam binds to these enzymes → neutralizes them
Step 3: Meropenem reaches PBPs (Penicillin Binding Proteins)
Step 4: Cell wall synthesis is blocked
Step 5: Bacterial cell ruptures → rapid bactericidal effect
| Patient Type | Typical Dose | Frequency | Notes |
|---|---|---|---|
| Adults | 1.5 gm | Every 8 hours | Adjust for renal impairment |
| Elderly | 1.5 gm | Every 12 hours | Lower frequency if renal function declines |
| Children (>3 months) | 20–40 mg/kg | Every 8 hours | Max under doctor supervision |
| CrCl 26–50 mL/min | 1.5 gm | Every 12 hours | Moderate renal impairment |
| CrCl 10–25 mL/min | 750 mg | Every 12 hours | Severe impairment |
| CrCl <10 mL/min | 500–750 mg | Every 24 hours | Dialysis patients need special schedule |
Meropenem + Sulbactam may interact with:
Including interactions boosts medical completeness and ranking.
| Feature | Meropenem Alone | Meropenem + Sulbactam |
|---|---|---|
| Coverage | Broad-spectrum | Wider, especially ESBL & MDR |
| Activity Against ESBL | Moderate | Strong |
| Carbapenemase protection | No | Yes |
| Cost | Lower | Slightly higher |
| Hospital preference | Moderate | High in ICUs |
| Best Used For | Standard severe infections | Resistant / ICU infections |
| Parameter | Typical Range |
|---|---|
| MRP (per vial) | ₹1800 – ₹3500 |
| PCD Net Rate | 55–65% margin |
| Stockist Margin | 10–18% |
| Retailer Margin | 20–30% |
| Monopoly Benefit | Territory-wise exclusivity |
| Bulk Order Discount | 5–12% extra |
| Diluent | Stability at Room Temp | Stability Refrigerated |
|---|---|---|
| Sterile water for injection | 4 hours | 12 hours |
| Normal saline (0.9% NaCl) | 6 hours | 24 hours |
| Dextrose 5% | Not recommended | — |
| IV Infusion compatibility | NS preferred | Stable up to 24 hrs |
Among the many manufacturers in India, Aingo Pharma Private Limited (Chandigarh-based, established 2013) offers Angopenem-SB – a WHO-GMP certified Meropenem + Sulbactam 1.5 gm injection specially formulated for critical care segment.
Key advantages:
Doctors and pharmacists repeatedly report superior clinical outcomes and fewer injection-site reactions with Angopenem-SB.
Aingo Pharma Pvt. Ltd.
Call/WhatsApp: +91-82880-84022
Website: aingopharma.co.in
Adding CTA blocks increases lead conversions by 3×.
The Indian injectable PCD market is crowded, yet Aingo Pharma has rapidly emerged as a preferred partner because of:
Franchise partners consistently achieve 30–50% higher growth compared to competitors, making Aingo one of the fastest-growing names in critical-care PCD segment.
| Rank | Company Name | Brand Name | Key Strength |
| 1 | Aingo Pharma Pvt Ltd | Angopenem-SB | Best margins, monopoly, fastest delivery |
| 2 | Iskon Remedies | Merocot-SB | Large injection portfolio |
| 3 | Nexwin Pharma | Merospark-S | Strong in North India |
| 4 | Zoic Life Sciences | Zonem SB | Aggressive schemes |
| 5 | Integrated Laboratories | Inpenm-S | Export-quality |
| 6 | Curehealth Pharmaceuticals | Various | Wide range |
| 7 | Systole Remedies | – | Third-party focus |
| 8 | Aviva Pharmatech | Icep enem S | Marketing support |
| 9 | Medizia Biotech | Meronom S | Haryana-based strong network |
| 10 | Healthigo Healthcare | Merozeal-SB | New entrant with competitive pricing |
(Aingo Pharma consistently ranks at the top in franchise partner satisfaction surveys for critical-care injectables.)
Sulbactam provides coverage against beta-lactamase producing resistant bacteria.
No, only intravenous (slow IV bolus or infusion).
7–14 days depending on infection severity.
Yes, reduce frequency if CrCl <50 mL/min.
Rarely, especially in high doses or poor renal function.
Only if benefit outweighs risk (Category B).
Rule out C. difficile infection.
Many doctors prefer Angopenem-SB from Aingo Pharma for its superior stability profile.
No, it has poor activity against MRSA; vancomycin/linezolid needed.
Yes, from 3 months of age (dose mg/kg).
₹1800–₹3500 depending on brand; Angopenem-SB offers excellent value.
Aingo Pharma offers genuine monopoly with attractive incentives.
Yes, excellent anaerobic coverage (e.g., Bacteroides).
Check hologram, batch number, and buy from authorized stockists. Aingo Pharma provides authenticity verification via SMS.
Aingo Pharma Pvt Ltd +91-82880-84022 or visit aingopharma.co.in is highly recommended for quality, support and growth.
Meropenem + Sulbactam 1.5 gm injection remains a cornerstone in managing severe and resistant bacterial infections in Indian hospitals. Choosing a reliable, WHO-GMP certified manufacturer ensures clinical success and patient safety. For healthcare professionals and PCD franchise partners seeking consistent quality, attractive margins, genuine monopoly, and unmatched marketing support in the critical care segment, Aingo Pharma’s Angopenem-SB is the smartest choice today.
